Published • loading... • Updated
Fulcrum to Merge with Slate in All-Stock Deal After Drug Setback
The combined biotech will keep Slate’s name and ticker as it adds a migraine antibody and financing expected to fund operations into 2029.
- On Monday, Fulcrum Therapeutics announced a definitive agreement to merge with privately held Slate Medicines in an all-stock transaction, creating a combined entity operating under the Slate Medicines name and trading on Nasdaq under ticker "SLTE."
- Fulcrum sought strategic alternatives after discontinuing development of pociredir, its lead sickle cell drug, last month when the FDA flagged potential cancer risks, prompting an 85% workforce reduction to nine employees.
- Concurrent with the merger, Slate secured $245 million in private placement financing led by Frazier Life Sciences, with the combined capital expected to fund operations into 2029.
- Led by Slate Medicines CEO Gregory Oakes, the combined company will prioritize SLTE-1009, a clinical-stage antibody targeting PACAP and VIP for migraine prevention.
- The company targets the $5 billion global migraine market, aiming to offer enhanced efficacy through mid-stage development of SLTE-1009 and an additional undisclosed program.
Insights by Ground AI
13 Articles
13 Articles
Fulcrum to merge with Slate in all-stock deal after drug setback
·London, United Kingdom
Read Full Article
Slate Medicines’ Merger and $245M Private Placement Fuel Mission in Migraine
Migraine drugs developer Slate Medicines is going public in a reverse merger with Fulcrum Therapeutics. The biotech’s lead antibody drug blocks two novel migraine targets, offering the potential for better efficacy compared to other next-generation migraine drugs in R&D.
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies
Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-generation migraine therapeutics Slate’s lead product candidate, SLTE-1009,...
·Manila, Philippines (the)
Read Full ArticleCoverage Details
Total News Sources13
Leaning Left0Leaning Right2Center7Last UpdatedBias Distribution78% Center
Bias Distribution
- 78% of the sources are Center
78% Center
C 78%
R 22%
Factuality
To view factuality data please Upgrade to Premium
